Patents by Inventor Thomas Alan Crowell

Thomas Alan Crowell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Naphthyl compounds, intermediates, compositions, and methods of use
    Patent number: 7105541
    Abstract: The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: September 12, 2006
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones
  • Naphthyl compounds, intermediates, compositions, and methods of use
    Patent number: 6812244
    Abstract: The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Thomas Alan Crowell, Charles David Jones, Alan David Palkowitz
  • Naphthyl compounds, intermediates, compositions, and methods of use
    Publication number: 20040072820
    Abstract: The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.
    Type: Application
    Filed: May 27, 2003
    Publication date: April 15, 2004
    Inventors: Henry Uhlman Bryant, Thomas Alan Crowell, Charles David Jones, Alan David Palkowitz
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6617347
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones, Anthony John Shuker
  • Naphthalene compounds, intermediates, formulations, and methods
    Patent number: 6599920
    Abstract: This invention relates to the field of pharmaceutical and organic chemistry and provides naphthalene compounds, intermediates, formulations, and methods.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: July 29, 2003
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Thomas Alan Crowell, Charles David Jones
  • Naphthyl compounds, intermediates, compositions, and methods of use
    Patent number: 6593345
    Abstract: The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: July 15, 2003
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Thomas Alan Crowell, Charles David Jones, Alan David Palkowitz
  • NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS
    Publication number: 20030100754
    Abstract: This invention relates to the field of pharmaceutical and organic chemistry and provides naphthalene compounds, intermediates, formulations, and methods.
    Type: Application
    Filed: August 26, 1997
    Publication date: May 29, 2003
    Inventors: HENRY UHLMAN BRYANT, THOMAS ALAN CROWELL, CHARLES DAVID JONES
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6265581
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6232337
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of formula (I) or a pharmaceutically acceptable salt thereof. The variables of formula (I) have the meanings defined herein.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: May 15, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones, Anthony John Shuker
  • Selective .beta.-3 adrenergic agonists
    Patent number: 6093735
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta..sub.3 adrenergic agonists
    Patent number: 6075040
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: June 13, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 6060492
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: May 9, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 6046227
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta..sub.3 receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: April 4, 2000
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones, Anthony John Shuker
  • Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
    Patent number: 6020513
    Abstract: The instant invention provides dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods for use in the treatment of bone loss or bone resorption.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: February 1, 2000
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Thomas Alan Crowell, Charles David Jones
  • Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
    Patent number: 5958916
    Abstract: The instant invention provides dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods for use in the treatment of bone loss or bone resorption.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: September 28, 1999
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Thomas Alan Crowell, Charles David Jones
  • Benzofluorene compounds, intermediates, compositions, and methods
    Patent number: 5958917
    Abstract: The present invention provides compounds of formula I ##STR1## wherein R.sub.1 is --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.6 alkyl), --OCOO(C.sub.1 -C.sub.6 alkyl), --OCOAr, --OCOOAr, or --OSO.sub.2 (C.sub.2 -C.sub.6 alkyl);R.sub.2 is --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.6 alkyl), --OCOO(C.sub.1 -C.sub.6 alkyl), --OCOAr, --OCOOAr, or --OSO.sub.2 (C.sub.2 -C.sub.6 alkyl);R.sub.3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; andn is 2 or 3;or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: September 24, 1997
    Date of Patent: September 28, 1999
    Assignee: Eli Lilly and Company
    Inventors: Thomas Alan Crowell, Charles David Jones, Henry Uhlman Bryant
  • Selective .beta.3 adrenergic agonists
    Patent number: 5939443
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Donald Paul Matthews, John Hampton McDonald, III, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.-3 adrenergic agonists
    Patent number: 5840738
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta.3 adrenergic agonists
    Patent number: 5808080
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: September 15, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, David Andrew Neel, Mark Alan Winter
  • Dihydrobenzofluorene compounds, intermediates, compositions and methods
    Patent number: 5792762
    Abstract: The invention provides dihydronaphthofluorene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: August 11, 1998
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Thomas Alan Crowell, Charles David Jones